Athira Pharma (NASDAQ:LONA – Get Free Report) had its price objective dropped by equities researchers at Mizuho from $13.00 to $12.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Mizuho‘s target price would suggest a potential upside of 492.30% from the company’s current price.
Other equities research analysts also recently issued research reports about the company. Wall Street Zen raised Athira Pharma to a “hold” rating in a report on Saturday, October 17th. Citizens Jmp dropped their target price on Athira Pharma from $17.00 to $16.00 and set a “market outperform” rating on the stock in a research report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a report on Wednesday, November 4th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $16.00.
View Our Latest Stock Analysis on Athira Pharma
Athira Pharma Stock Performance
Athira Pharma (NASDAQ:LONA – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.27). Analysts predict that Athira Pharma will post -2.85 EPS for the current fiscal year.
Athira Pharma Company Profile
Athira Pharma is a clinical-stage biopharmaceutical company based in Bothell, Washington, that focused on developing treatments for neurodegenerative diseases and other conditions affecting the brain. Its research centered on the hepatocyte growth factor (HGF) and MET biological system, which is involved in neuronal health and repair. The company’s pipeline included fosgonimeton, an investigational therapy studied for Alzheimer’s disease and dementia associated with Parkinson’s disease, as well as ATH-1105, a small-molecule candidate investigated for amyotrophic lateral sclerosis.
Further Reading
- Five stocks we like better than Athira Pharma
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
